Today: 10 June 2026
Palantir stock slips before the bell as tariff doubts rattle tech — what investors watch next
23 February 2026
2 mins read

Palantir stock slips before the bell as tariff doubts rattle tech — what investors watch next

New York, February 23, 2026, 07:17 ET — Premarket

  • Palantir fell about 1.4% before the bell, after closing Friday at $135.24.
  • Appetite for risk faded from growth stocks, with renewed U.S. tariff uncertainty back in focus.
  • This week’s spotlight falls on earnings from big AI and software companies, with traders looking for any hints about enterprise IT budgets.

Palantir Technologies Inc (PLTR) slipped 1.4% in premarket action Monday, quoted near $133.33 after closing out last week at $135.24. Volume before the open came in a touch above 153,000 shares.

Fresh trade nerves hit traders after President Donald Trump announced a new 15% global tariff, despite the Supreme Court’s move Friday to scrap most of last year’s tariffs. “It’s really hard … to know how do you plan,” said Arthur Laffer Jr., president of Laffer Tengler Investments, as uncertainty continues to cloud suppliers and the broader supply chain. Nvidia’s earnings are set for Wednesday; results from Salesforce and Intuit are also on deck. The S&P 500 software and services index has already taken a notable hit this year. Reuters

Palantir CEO Alex Karp is looking to sell 403,025 shares, according to a Form 144 filing that dropped late Friday. The haul? About $53.9 million at current prices. Form 144 lets insiders flag when they plan to shed restricted shares under Rule 144.

Palantir’s most recent earnings report dropped on Feb. 2, with fourth-quarter revenue jumping 70% to $1.41 billion. U.S. commercial business more than doubled—up 137% to $507 million. “We are an n of 1,” CEO Alex Karp said in the statement. The company put its 2026 revenue forecast between $7.182 billion and $7.198 billion, while cautioning that broader macro pressures, like tariffs, could disrupt its customers and partners. SEC

The company listed about 2.29 billion Class A shares outstanding as of Feb. 10, according to its annual filing published Feb. 17.

Palantir, known for its data-analysis software, counts both government agencies and corporations among its customers. Lately, its AI-driven products have made the stock a high-beta play on enterprise AI spending: shares can rocket on strong growth signals, but they’ve also been hit hard when investors pull back on risk.

At the moment, the stock trades in sync with broad macro swings—not its own fundamentals. When tariffs or growth worries flare up, investors waste no time unloading pricey software names, with real company numbers taking a back seat until later.

Things can shift quickly. If tariff headlines turn into real restrictions that curb budgets or delay IT deployments, Palantir could watch its multiple contract once more—even as revenues keep rising.

Investors are pressing for details: when the tariff plan rolls out, what the legal language looks like, how real the threat is for corporate planning. There’s also some focus on insider sale notices—traders are watching if those filings translate into heavier selling once the market’s back to normal liquidity after the open.

Nvidia is set to report its quarterly earnings on Feb. 25—a date investors have marked as they hunt for any signals about current AI demand. The implications go further than Nvidia’s results. For software names tied to enterprise AI spending, Nvidia’s commentary offers clues they can’t afford to miss.

Stock Market Today

  • Netflix Stock Price Target Cut Amid Few Growth Catalysts
    June 10, 2026, 3:12 PM EDT. A Wall Street analyst lowered the price target for Netflix, citing a lack of short-term catalysts to boost the stock. The streaming giant faces challenges in driving subscriber growth and revenue momentum, leading to cautious investor sentiment. The price target cut reflects concerns over limited near-term drivers amid intensifying competition in the streaming market. Netflix's share price has seen pressure as analysts reassess the company's growth outlook and monetization potential. Investors are advised to watch for strategic moves or content successes that could reignite interest in the stock.

Latest articles

Pop Culture Group CPOP jumps on half-year results but rally tested

Pop Culture Group CPOP jumps on half-year results but rally tested

10 June 2026
Pop Culture Group shares soared 378% to $1.72 after reporting half-year revenue up 65% to $68.9 million, driven by a 79% surge in digital entertainment, now 97% of sales, but thin 3% gross margin, net profit drop, Bitcoin-linked losses, and heavy reliance on share sales raise questions about sustainability amid repeated Nasdaq volatility halts.
Delta Shares Drop After Fuel Spike Jolts Airline Rally

Delta Shares Drop After Fuel Spike Jolts Airline Rally

10 June 2026
Delta shares plunged 5.1% to $77.01 as surging oil prices reignited fears over jet-fuel costs, threatening Delta’s margin guidance and testing whether fare hikes and capacity cuts can keep up with rising expenses; investors now await Delta’s June-quarter update for signs that higher ticket prices are offsetting fuel shocks.
Webull Shares Climb; BULL Call Options Activity Rises as Retail Traders Pile In

Webull Shares Climb; BULL Call Options Activity Rises as Retail Traders Pile In

10 June 2026
Webull shares soared 11.9% to $6.16 as traders piled into short-dated call options, driving volume above average, following a recent FINRA rule change that eliminated the $25,000 minimum and day trade limits for small accounts—raising hopes for increased trading activity but leaving questions about whether higher costs will offset potential revenue gains.
CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares
Previous Story

CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop